GLP1R and type 2 diabetes mellitus: Clinical trials, like LEADER (liraglutide) and SUSTAIN-6 (semaglutide), demonstrated that GLP-1 analogs reduce the risk of cardiovascular events in T2DM patients, an effect beyond glycemic control [233, 234].